Eftozanermin alfa

• Description:

  Eftozanermin alfa (ABBV-621) is a tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa is a fusion protein consisting of a mutant immunoglobulin G1-Fc linked to 2 single-chain trimers of TRAIL. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors (DR4 receptor and DR5 receptor) with Kds of 780 nM and 635 nM. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies[1][2][3].

• Product Name Alternative:

  ABBV-621

• UNSPSC:

  12352203

• Target:

  Apoptosis; Caspase; TNF Receptor

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/eftozanermin-alfa.html

• Purity:

  98.86

• Solubility:

  H2O

• Smiles:

  [Eftozanerminalfa]

• Molecular Weight:

  (167.52 kDa)

• References & Citations:

  [1]Tahir SK, et al. Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. Blood. 2023 Jan 30:blood.2022017333.|[2]Silva A S, et al. Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma. Blood, 2020, 136 (Supplement 1) :49-50.|[3]Phillips DC, et al. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors. Cancer Res. 2021 Jun 15;81 (12) :3402-3414.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 1

• Isoform:

  Caspase 3; Caspase 7; Caspase 8

• CAS Number:

  [1820660-69-2]